

Report of Head and Neck Cancer Registry of Japan  
Five-year Prognosis of Patients Registered in 2015

Japan Society for Head and Neck Cancer  
Cancer Registry Committee

Primary tumor site	Number of patients	%
1) Oral cavity	2430	24.3
2) Nasal cavity, etc.	712	7.1
3) Nasopharynx	302	3.0
4) Oropharynx	1589	15.9
5) Hypopharynx	2227	22.3
6) Larynx	2175	21.8
7) Major salivary glands	555	5.6
Total	9990	100

Nasal cavity, etc.: nasal cavity and paranasal sinuses

	<b>MFT to relapse (month; range)</b>	<b>MFT to death or last follow-up (month)</b>	<b>Death or last follow-up</b>	<b>in 2015</b>	<b>in 2016</b>	<b>in 2017</b>	<b>in 2018</b>	<b>in 2019</b>	<b>after 2020</b>
1) Oral cavity	30.54 (0.03-95.01)	51.1		152(20.3%)	256(34.1%)	104(13.9%)	75(10.0%)	58(7.7%)	105(14.0%)
2) Nasal cavity, etc.	15.15 (0.03-88.34)	25.7		72(25.3%)	109(38.2%)	42(14.7%)	16(5.6%)	17(6.0%)	29(10.2%)
3) Nasopharynx	25.92(0.03-84.72)	46.1		18(17.7%)	36(35.3%)	16(15.7%)	7(6.9%)	6(5.9%)	19(18.6%)
4) Oropharynx	28.52(0.03-87.39)	50.8		110(20.8%)	169(31.9%)	79(14.9%)	44(8.3%)	39(7.4%)	88(16.6%)
5) Hypopharynx	19.84(0.03-96.42)	35.0		168(18.2%)	294(31.9%)	182(19.7%)	107(11.6%)	66(7.2%)	106(11.5%)
6) Larynx	43.82(0.03-90.37)	58.7		56(12.1%)	114(24.7%)	76(16.5%)	70(15.2%)	41(8.9%)	104(22.6%)
7) Major salivary glands	24.15(0.07-94.61)	47.0		31(17.9%)	48(27.7%)	33(19.1%)	21(12.1%)	13(7.5%)	27(15.6%)

Nasal cavity, etc.: nasal cavity and paranasal sinuses

\*Abbreviation: MFT; Median follow-up time.

Relapse lesion	Number of Patients (Number of DOD)											
	1) Oral cavity	2) Nasal cavity, etc.	3) Nasopharynx	4) Oropharynx	5) Hypopharynx	6) Larynx	7) Major salivary glands					
No	1590 ( 26 )	365 ( 15 )	187 ( 1 )	1046 ( 27 )	1306 ( 38 )	1747 ( 23 )	347 ( 3 )					
Local	228 ( 93 )	90 ( 35 )	11 ( 7 )	135 ( 58 )	207 ( 74 )	165 ( 30 )	25 ( 10 )					
Regional	241 ( 88 )	35 ( 10 )	17 ( 8 )	91 ( 40 )	157 ( 76 )	65 ( 22 )	27 ( 12 )					
Distant	102 ( 63 )	61 ( 38 )	39 ( 6 )	104 ( 66 )	220 ( 146 )	74 ( 39 )	81 ( 48 )					
Local+Regional	43 ( 25 )	11 ( 4 )	1 ( 26 )	20 ( 8 )	31 ( 22 )	10 ( 8 )	5 ( 3 )					
Local+Distant	20 ( 14 )	16 ( 12 )	1 ( 1 )	4 ( 3 )	11 ( 8 )	5 ( 1 )	5 ( 4 )					
Regional+Distant	20 ( 18 )	10 ( 7 )	1 ( 1 )	15 ( 11 )	40 ( 33 )	14 ( 9 )	9 ( 4 )					
Local+Regional+Distant	12 ( 10 )	3 ( 2 )	1 ( 1 )	9 ( 9 )	11 ( 8 )	1 ( 1 )	1 ( 1 )					
Undecidable	131 ( 82 )	104 ( 69 )	35 ( 24 )	135 ( 82 )	202 ( 137 )	62 ( 30 )	44 ( 28 )					
Unknown	43 ( 4 )	17 ( 1 )	9 ( 1 )	30 ( 3 )	42 ( 12 )	32 ( 1 )	11 ( 2 )					
<b>Total</b>	<b>2430 ( 423 )</b>	<b>712 ( 193 )</b>	<b>302 ( 76 )</b>	<b>1589 ( 307 )</b>	<b>2227 ( 554 )</b>	<b>2175 ( 164 )</b>	<b>555 ( 115 )</b>					

Nasal cavity, etc.: nasal cavity and paranasal sinuses

\*Abbreviation: DOD; Death of Disease.

Disease stage	1) Oral cavity	2) Nasal cavity, etc.	3) Nasopharynx	4) Oropharynx	5) Hypopharynx	6) Larynx	7) Major salivary glands
	Median follow-up time to death or last follow-up (month)						
0	64.1	43.6	-	69.1	66.0	68.2	-
1	60.3	52.4	66.2	59.7	60.8	61.0	62.0
2	60.2	61.3	62.0	57.3	53.3	56.7	60.4
3	46.6	50.9	42.1	60.9	44.5	58.0	64.9
4a	26.0	24.6	43.3	53.5	26.3	33.0	31.5
4b	13.8	14.8	28.6	18.2	14.8	12.8	6.8
4c	11.3	5.7	16.2	10.0	7.0	15.1	8.5
Unknown	34.5	20.7	62.4	43.8	44.1	61.4	62.8

Nasal cavity, etc.: nasal cavity and paranasal sinuses

**Number of metachronous multiple cancer by primary tumor site (pre- / post-primary cancer)**

	No	Head and Neck	Esophagus	Lung	Stomach	Liver	Colon	Others	Unknown	No reported
1) Oral cavity	968/996	85/68	43/32	12/37	28/17	0/4	23/14	48/41	14/21	1241/1220
2) Nasal cavity, etc.	250/251	4/4	3/2	6/4	4/5	0/3	3/1	4/8	9/8	431/427
3) Nasopharynx	105/106	5/2	0/0	1/1	1/0	0/2	1/0	3/5	2/2	186/184
4) Oropharynx	533/560	65/61	65/36	10/26	25/16	3/12	12/9	17/31	10/10	877/861
5) Hypopharynx	630/672	82/130	230/131	23/62	55/33	6/7	37/14	29/40	9/12	1200/1188
6) Larynx	835/813	23/35	35/39	29/70	35/32	7/5	17/18	33/57	18/29	1168/1111
7) Major salivary glands	213/210	2/7	1/4	1/7	3/2	0/1	3/0	11/5	5/6	317/316

Nasal cavity, etc.: nasal cavity and paranasal sinuses

**Number of clinical outcome by primary tumor site**

	Survival (%)	Death of primary cancer (%)	Death of other cancer (%)	Death of other disease (%)	Death of unknown cause (%)	Unknown (%)	total (%)
1) Oral cavity	1680 ( 69.1 )	423 ( 17.4 )	71 ( 2.9 )	90 ( 3.7 )	29 ( 1.2 )	137 ( 5.6 )	2430 ( 100 )
2) Nasal cavity, etc.	427 ( 60.0 )	193 ( 27.1 )	12 ( 1.7 )	21 ( 2.9 )	17 ( 2.4 )	42 ( 5.9 )	712 ( 100 )
3) Nasopharynx	200 ( 66.2 )	70 ( 23.2 )	6 ( 2.0 )	7 ( 2.3 )	2 ( 0.7 )	17 ( 5.6 )	302 ( 100 )
4) Oropharynx	1060 ( 66.7 )	307 ( 19.3 )	45 ( 2.8 )	62 ( 3.9 )	23 ( 1.4 )	92 ( 5.8 )	1589 ( 100 )
5) Hypopharynx	1304 ( 58.6 )	554 ( 24.9 )	104 ( 4.7 )	95 ( 4.3 )	41 ( 1.8 )	129 ( 5.8 )	2227 ( 100 )
6) Larynx	1714 ( 78.8 )	164 ( 7.5 )	90 ( 4.1 )	78 ( 3.6 )	29 ( 1.3 )	100 ( 4.6 )	2175 ( 100 )
7) Major salivary glands	382 ( 68.8 )	115 ( 20.7 )	5 ( 0.9 )	9 ( 1.6 )	3 ( 0.5 )	41 ( 7.4 )	555 ( 100 )

Nasal cavity, etc.: nasal cavity and paranasal sinuses